Literature DB >> 9634546

Role of CD44 in CTL and NK cell activity.

A Q Rafi-Janajreh1, P S Nagarkatti, M Nagarkatti.   

Abstract

CD44 is a widely distributed cell surface glycoprotein whose principal ligand has been identified as hyaluronic acid (HA), a major component of the extracellular matrix (ECM). Recent studies have demonstrated that activation through CD44 leads to induction of effector function in T cells and macrophages. At sites of chronic inflammation as seen in certain infections, autoimmune diseases, allograft rejection, graft-versus-host (GVH) disease and treatment of cancer patients with high doses of interleukin-2, significant damage to the endothelial cells has been known to occur, which leads to the toxicity or pathogenesis associated with the disease. The exact mechanism of endothelial cell damage is not clear, although, it has been widely speculated that immune cells may play a critical role. Studies from our laboratory have used interleukin-2 (IL-2) induced vascular leak syndrome (VLS) as a model to investigate the role of cytolytic lymphocytes in the direct cytotoxicity of endothelial cells. Cytotoxic T lymphocytes (CTL), double-negative (DN) T cells and natural killer (NK) cells upon activation express high levels of CD44 and mediate efficient MHC-unrestricted TCR-independent lysis following ligation of CD44. Such CD44-mediated cytotoxicity may play an important role in protection against viral infections and cancer. However, it could also cause non-specific tissue injury. For example, dysregulation in the interaction between activated cytotoxic lymphocytes expressing CD44 and endothelial cells bearing the appropriated ligand such as the hyaluronate (HA), could lead to endothelial cell lysis. Furthermore, such endothelial cell injury could lead to the pathogenesis associated with a variety of clinical diseases.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9634546     DOI: 10.2741/a311

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  8 in total

1.  Unique SNP in CD44 intron 1 and its role in breast cancer development.

Authors:  Juhua Zhou; Prakash S Nagarkatti; Yin Zhong; Kim Creek; Jiajia Zhang; Mitzi Nagarkatti
Journal:  Anticancer Res       Date:  2010-04       Impact factor: 2.480

2.  CD44 mobilization in allogeneic dendritic cell-T cell immunological synapse plays a key role in T cell activation.

Authors:  Venkatesh L Hegde; Narendra P Singh; Prakash S Nagarkatti; Mitzi Nagarkatti
Journal:  J Leukoc Biol       Date:  2008-04-03       Impact factor: 4.962

3.  Implications of single nucleotide polymorphisms in CD44 exon 2 for risk of breast cancer.

Authors:  Juhua Zhou; Prakash S Nagarkatti; Yin Zhong; Jiajia Zhang; Mitzi Nagarkatti
Journal:  Eur J Cancer Prev       Date:  2011-09       Impact factor: 2.497

4.  Ectopic expression of CD74 in Ikkβ-deleted mouse hepatocytes.

Authors:  Katherine S Koch; Hyam L Leffert
Journal:  Acta Histochem       Date:  2010-06-01       Impact factor: 2.479

5.  Characterization of T-cell memory phenotype after in vitro expansion of tumor-infiltrating lymphocytes from melanoma patients.

Authors:  Juhua Zhou; Prakash Nagarkatti; Yin Zhong; Mitzi Nagarkatti
Journal:  Anticancer Res       Date:  2011-12       Impact factor: 2.480

6.  CD44 Reciprocally regulates the differentiation of encephalitogenic Th1/Th17 and Th2/regulatory T cells through epigenetic modulation involving DNA methylation of cytokine gene promoters, thereby controlling the development of experimental autoimmune encephalomyelitis.

Authors:  Hongbing Guan; Prakash S Nagarkatti; Mitzi Nagarkatti
Journal:  J Immunol       Date:  2011-05-06       Impact factor: 5.422

7.  Role of CD44 in the differentiation of Th1 and Th2 cells: CD44-deficiency enhances the development of Th2 effectors in response to sheep RBC and chicken ovalbumin.

Authors:  Hongbing Guan; Prakash S Nagarkatti; Mitzi Nagarkatti
Journal:  J Immunol       Date:  2009-07-01       Impact factor: 5.422

8.  Comprehensive Screening of Gene Function and Networks by DNA Microarray Analysis in Japanese Patients with Idiopathic Portal Hypertension.

Authors:  Kohei Kotani; Joji Kawabe; Hiroyasu Morikawa; Tomohiko Akahoshi; Makoto Hashizume; Susumu Shiomi
Journal:  Mediators Inflamm       Date:  2015-10-04       Impact factor: 4.711

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.